Exendin-4 may improve type 2 diabetes by modulating the epigenetic modifications of pancreatic histone H3 in STZ-induced diabetic C57BL/6 J mice
J. physiol. biochem
; 78(1): 51-59, feb. 2022.
Article
in English
| IBECS
| ID: ibc-215872
Responsible library:
ES1.1
Localization: ES15.1 - BNCS
ABSTRACT
Type 2 diabetes (T2D) is a complicated systemic disease that might be improved by exendin-4, although the epigenetic role remains unclear. In the current study, C57BL/6 J mice were used to generate a T2D model, followed by treatment with exendin-4 (10 μg/kg). Histone H3K9 and H3K23 acetylation, H3K4 mono-methylation, and H3K9 di-methylation were explored by western blot analysis of pancreatic histone extracts. Real-time polymerase chain reaction (PCR) was used to examine the expression levels of pancreatic beta cell development-related genes, and chromatin immunoprecipitation (ChIP) was applied to analyze H3 and H3K9 acetylation, H3K4 mono-methylation, and H3K9 di-methylation in the promoter region of the pancreatic and duodenal homeobox 1 (Pdx1) gene. The results showed that total H3K9 di-methylation and H3K9 and H3K23 acetylation increased in pancreatic tissues of diabetic mice, whereas H3K4 mono-methylation was reduced. All of these changes could be abrogated by treatment with exendin-4. Our data indicated that T2D progression might be improved by exendin-4 treatment through the reversal of global pancreatic histone H3K9 and H3K23 acetylation, H3K4 mono-methylation, and H3K9 di-methylation. A better understanding of these epigenetic alterations may, therefore, lead to novel therapeutic strategies for T2D. (AU)
Search on Google
Collection:
National databases
/
Spain
Database:
IBECS
Main subject:
Diabetes Mellitus, Experimental
/
Diabetes Mellitus, Type 2
Limits:
Animals
Language:
English
Journal:
J. physiol. biochem
Year:
2022
Document type:
Article
Institution/Affiliation country:
Anhui Medical University/China
/
Huaibei Miner General Hospital/China
/
Nankai University/China
/
Tianjin Agricultural University/China